Genomic Classification and Prognosis in Acute Myeloid Leukemia
Explore this paper's citation graph
Summary
The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification and require validation in prospective clinical trials.
- Type
- article
- Published
- 2016-06-08
- Cited by
- 3,573
- References
- 40
- Access
- Open access
- OpenAlex
- https://openalex.org/W2419140434
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205099707
Keywords
NPM1, Myeloid leukemia, Medicine, Mutation, Genetics
References
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- Penalized Survival Models and Frailty
- Clinical and biological implications of driver mutations in myelodysplastic syndromes.
- Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis
- Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
- The origin and evolution of mutations in Acute Myeloid Leukemia
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- Cooperative loss of RAS feedback regulation drives myeloid leukemognesis
- Genetic variegation of clonal architecture and propagating cells in leukaemia
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
- Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
- The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization*
- Mutations and prognosis in primary myelofibrosis
- Implications of NRAS mutations in AML: a study of 2502 patients.
- Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
- Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis
- Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
Cited by
- Clinical Trials in the Genomic Era.
- Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
- Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
- Pharmacogenetics and Personalized Medicine in Hematology
- Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history
- Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia
- Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases
- Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
- Can we forecast induction failure in acute myeloid leukemia?
- Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis
- Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.
- The complexity of stem cell transplants: can we improve our understanding?
- Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission
- The splicing factor RBM25 controls MYC activity in acute myeloid leukemia
- Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
- Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
- Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
- Leucemia mieloide aguda
- Akute myeloische Leukämie
- Acfs: accurate circRNA identification and quantification from RNA-Seq data
Related papers
- NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
- AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
- Molecular Detection of Type A Nucleophosmin Mutation for the First Time in Forty Four Iraqi Patients with AML: Correlation with prognosis
- Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia
- POSTER: AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
- [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
- Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice
- [Research on NPM1 gene mutations in acute myeloid leukemia].
- Clinical characteristics of NPM1 gene mutation in acute myelogenous leukemia
- Nucleophosmin gene mutations in acute myeloid leukemia.